00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
00:01 , Apr 30, 2019 |  BioCentury  |  Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
22:55 , Feb 22, 2019 |  BioCentury  |  Finance

MPM keeps building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy. BioVentures 2018 closed on Feb. 21 and follows in the footsteps of...
19:08 , Feb 22, 2019 |  BC Week In Review  |  Financial News

MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such...
20:16 , Feb 21, 2019 |  BC Innovations  |  Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
12:00 , Feb 21, 2019 |  BC Extra  |  Financial News

MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such...
05:01 , Feb 5, 2019 |  BC Extra  |  Financial News

Real-world analytics company Aetion tops off series B

Aetion Inc. (New York, N.Y.) raised an additional $27 million in its series B round Tuesday to continue building its real-world evidence analytics platform. New investors Sanofi (Euronext:SAN; NASDAQ:SNY), UCB S.A. (Euronext:UCB), McKesson Ventures and...